Abstract
Targeted therapies affecting specific molecular target, expressed preferentially by neoplastic cells, block cancer growth. Current targets are represented by cell-surface trans-membrane proteins, intracellular proteins, and by growth factors. Today a targeted therapy exists for most commonly diagnosed types of human cancer often combined with chemotherapy or sometimes as monotherapy option. The epidermal growth factor receptors (EGFR) and vascular endothelial growth factors (VEGF) are known as the two main control key intracellular pathways, governing fundamental processes in cancer cells. The concept of using anti-EGFR and anti-VEGF strategies, as cancer treatment, has been recently developed and exploited extensively. We review targeted drugs currently available for routine treatment of lung, breast, colorectal and renal cell cancers, summarizing the history of identification and molecular characterization of targets or signaling pathways responsible for abnormal cell growth. We also focus on new targeted strategies, still under investigation, able to affect simultaneously tightly interconnected biological pathways or directed against new molecular targets.
Keywords: Target therapy, breast cancer, lung cancer, colorectal cancer, kidney cancer
Current Cancer Drug Targets
Title: Past, Present and Future of Targeted Therapy in Solid Tumors
Volume: 10 Issue: 5
Author(s): A. Palazzo, R. Iacovelli and E. Cortesi
Affiliation:
Keywords: Target therapy, breast cancer, lung cancer, colorectal cancer, kidney cancer
Abstract: Targeted therapies affecting specific molecular target, expressed preferentially by neoplastic cells, block cancer growth. Current targets are represented by cell-surface trans-membrane proteins, intracellular proteins, and by growth factors. Today a targeted therapy exists for most commonly diagnosed types of human cancer often combined with chemotherapy or sometimes as monotherapy option. The epidermal growth factor receptors (EGFR) and vascular endothelial growth factors (VEGF) are known as the two main control key intracellular pathways, governing fundamental processes in cancer cells. The concept of using anti-EGFR and anti-VEGF strategies, as cancer treatment, has been recently developed and exploited extensively. We review targeted drugs currently available for routine treatment of lung, breast, colorectal and renal cell cancers, summarizing the history of identification and molecular characterization of targets or signaling pathways responsible for abnormal cell growth. We also focus on new targeted strategies, still under investigation, able to affect simultaneously tightly interconnected biological pathways or directed against new molecular targets.
Export Options
About this article
Cite this article as:
Palazzo A., Iacovelli R. and Cortesi E., Past, Present and Future of Targeted Therapy in Solid Tumors, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517145
DOI https://dx.doi.org/10.2174/156800910791517145 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vivo Treatment Efficacy of Essential Oil Isolated from Seeds of <i>Momordica charantia</i> in Streptozotocin-Induced Diabetes Mellitus
Recent Patents on Biotechnology Tumor Biomarkers: Clinical Utility, Promises and Problems
Applied Clinical Research, Clinical Trials and Regulatory Affairs Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry Diterpenoids from Liverworts and their Biological Activities
Current Organic Chemistry Dissecting Virus-Plant Interactions Through Proteomics Approaches
Current Proteomics Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Combinatorial Chemistry & High Throughput Screening Antioxidant Effect of a Nitrated Cyclic Nucleotide Functioning as an Endogenous Electrophile
Current Topics in Medicinal Chemistry HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Antioxidant Therapeutic Approaches Toward Amelioration of the Pulmonary Pathophysiological Damaging Effects of Ionizing Irradiation
Current Respiratory Medicine Reviews Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis
Current Pharmaceutical Design Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) A New 4-phenyl-1,8-naphthyridine Derivative Affects Carcinoma Cell Proliferation by Impairing Cell Cycle Progression and Inducing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?
Recent Patents on Anti-Cancer Drug Discovery miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The ‘Minute and Miracle’ Molecule Moving as a Monitor in the ‘Genomic Galaxy’
Current Drug Targets Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review
Reviews on Recent Clinical Trials Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Advances in Translational Pharmacological Investigations in Identifying and Validating Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets